What is Pediatrics Respiratory Drugs Market Scope?
Respiratory diseases are pathological conditions affecting the organs and tissues that make gas exchange difficult during breathing. Respiratory disorders in infants and children are challenging problems for every clinician involved in the management of these patients. Before the rising prevalence of respiratory diseases in pediatrics has been the key factor for the growth of the pediatrics respiratory drugs market. Progressive increase in the obese pediatric population, changing lifestyle habits, and a surge in awareness about pediatric care are anticipated to increase expenditure on pediatric respiratory disease treatment, and this resulted in the growth of the global pediatrics respiratory drugs market in the forecast period.
The Pediatrics Respiratory Drugs market study is being classified and major geographies with country level break-up.
Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Pediatrics Respiratory Drugs market throughout the predicted period.
Abbott Laboratories (United States), Bayer (Germany), Eli Lilly (United States), Forest Laboratories (United States), AstraZeneca plc (United Kingdom), GlaxoSmithKline (United Kingdom), Johnson & Johnson (United States), Novartis Pharmaceuticals (Switzerland), Novo Nordisk (Denmark), Merck (United States) and Pfizer (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are F. Hoffmann-La Roche AG (Switzerland), Regeneron Pharmaceuticals (United States), Boehringer Ingelheim (Germany), MedImmune (United States), Zambon (Italy), Genentech (United States), Colgate Oral Pharmaceuticals (United States) and Bristol-Myers Squibb (United States).
Segmentation Analysis
Analyst at AMA have segmented the market study of Global Pediatrics Respiratory Drugs market by Type, Application and Region.
On the basis of geography, the market of Pediatrics Respiratory Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Influencers and their development strategies
On 25th July 2019, Zambon has announced the acquisition of Breath Therapeutics and its subsidiaries for euro 140 million (up to a total euro 500 million subject to regulatory and sales milestones). This combination will improve both companies’ ability to better serve patients and healthcare professionals in severe respiratory diseases, as well as accelerate the commercialization of these important new therapies.
On 28th September 2020, Pfizer Inc. has announced that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight.
Influencing Market Trend
- Rise in Awareness about Pediatric Care
Market Drivers
- Rising Prevalence of Chronic Respiratory Diseases in Pediatric
- Progressive Increase in Obese Pediatric Population
- Government and Non-government Organizations Focus on Campaigns to Increase Awareness about Pediatric Health
Opportunities
- Increasing Research and Development in Drug Discovery for Respiratory Diseases
Restraints
- Stringent Regulations for Drug Approval
Challenges
- Side Effects from Therapeutic drugs
Key Target Audience
Pediatrics Respiratory Drugs Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others
Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.